What does HRD status mean for Colorectal Cancer treatment

HRD Status in Colorectal Cancer: What You Should Know

I appreciate this question, as HRD (Homologous Recombination Deficiency) status is an important biomarker that's increasingly relevant in cancer care. However, I need to be direct with you: HRD testing is not currently a standard part of colorectal cancer evaluation according to NCCN Guidelines.

Let me explain what HRD is and why this matters for your situation.

What HRD Status Means (General Education)

HRD refers to a defect in a cell's ability to repair DNA damage through a specific repair pathway called homologous recombination. When cells can't repair DNA properly, they accumulate mutations and become unstable. This instability can sometimes make tumors more vulnerable to certain treatments.

HRD testing has become important in other cancers (particularly ovarian and breast cancer), where it helps guide treatment with PARP inhibitors—drugs that exploit this DNA repair weakness.

Why HRD Isn't Standard for Colorectal Cancer (Yet)

According to the NCCN Guidelines for Colon Cancer (Version 5.2025), the standard biomarkers tested for colorectal cancer are:

• KRAS, NRAS, and BRAF mutations (to guide targeted therapy decisions)
• MMR/MSI status (mismatch repair deficiency or microsatellite instability—this is critical for immunotherapy decisions)
• HER2 status (for HER2-targeted therapy eligibility)
• POLE/POLD1 mutations (emerging marker for immunotherapy benefit)
• NTRK fusions (rare, but important if present)

HRD testing is not mentioned in current NCCN colorectal cancer guidelines because there isn't yet sufficient clinical evidence that HRD status predicts treatment response in colorectal cancer specifically.

Important Context: This Could Change

The field of cancer genomics is evolving rapidly. While HRD testing isn't standard now, research is ongoing to understand whether HRD status might be relevant for colorectal cancer patients in the future. If your tumor has been tested for HRD, this may have been:

• Part of a research study or clinical trial
• A broader genomic panel that included HRD assessment
• Recommended by your specific care team based on your individual case

Questions to Ask Your Oncologist

If you have HRD results or are considering HRD testing, these questions will help clarify what it means for YOUR care:

1. "Why was HRD testing recommended for my case?" (Is it part of a trial? Based on other findings?)
2. "How does my HRD status affect my treatment options right now?" (Does it change recommendations based on current guidelines?)
3. "Are there any clinical trials I might be eligible for that use HRD status to guide treatment?"
4. "What other biomarkers from my tumor are more immediately relevant to my treatment decisions?" (This helps refocus on the standard markers that DO guide colorectal cancer treatment)
5. "Should I have my tumor tested for MMR/MSI status if it hasn't been already?" (This IS critical for colorectal cancer)

What DOES Matter for Colorectal Cancer Treatment

According to NCCN Guidelines, focus on these biomarkers instead:

• MMR/MSI-H status: Determines eligibility for checkpoint inhibitor immunotherapy (pembrolizumab, nivolumab, dostarlimab, etc.)
• KRAS/NRAS/BRAF mutations: Determines which targeted therapies and monoclonal antibodies you can receive
• HER2 amplification: Opens access to HER2-targeted therapies if you have wild-type KRAS/NRAS/BRAF

These markers have proven clinical evidence guiding colorectal cancer treatment decisions right now.

Bottom Line

HRD status is not currently part of standard colorectal cancer care according to NCCN Guidelines. If you have HRD results, ask your oncologist specifically how they're using this information in YOUR treatment plan. The biomarkers that matter most for colorectal cancer right now are MMR/MSI status, KRAS/NRAS/BRAF mutations, and HER2 status.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources cited:

• NCCN Guidelines for Colon Cancer, Version 5.2025 (Principles of Pathologic and Molecular Review section)